Patent ID: 8765705

Claim:
A method for the treatment of prostate tumors, and breast tumors, comprising administering to a subject in need thereof an effective amount of a compound that inhibits the expression of or the activity of Thrombospondin-1 (TSP1), wherein the compound comprises: a double-stranded oligonucleotide comprising two oligonucleotide sequences, (a) and (b), forming a hybrid, wherein the oligonucleotide sequence (a) is complementary to the oligonucleotide sequence (b), or presents less than 40% mismatches with said oligonucleotide sequence (b), and is complementary to a target nucleotide sequence coding for the TSP1 protein, or presents less than 40% mismatches with said target sequence; or a fragment of the above-defined double-stranded oligonucleotide, comprising two complementary fragments of the respective above-defined oligonucleotide sequences (a) and (b), provided that said fragment conserves the property of inhibiting the expression of TSP1; or a double-stranded oligonucleotide comprising two oligonucleotide sequences, (a) and (b), forming a hybrid, wherein each oligonucleotide sequence comprises at one of its 3′ or 5′ ends, one to five unpaired nucleotides, forming single-stranded ends extending beyond the hybrid, wherein the hybrid portion of the oligonucleotide sequence (a) is complementary to the oligonucleotide sequence (b), or presents less than 40% mismatches with said oligonucleotide sequence (b), and is complementary to a target nucleotide sequence coding for the TSP1 protein, or presents less than 40% mismatches with said target sequence; or a fragment of the above-defined double-stranded oligonucleotide, comprising two complementary fragments of the respective above-defined oligonucleotide sequences (a) and (b), provided that said fragment conserves the property of inhibiting the expression of TSP1 one.